325 related articles for article (PubMed ID: 30346481)
1. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.
Gross-Goupil M; Kwon TG; Eto M; Ye D; Miyake H; Seo SI; Byun SS; Lee JL; Master V; Jin J; DeBenedetto R; Linke R; Casey M; Rosbrook B; Lechuga M; Valota O; Grande E; Quinn DI
Ann Oncol; 2018 Dec; 29(12):2371-2378. PubMed ID: 30346481
[TBL] [Abstract][Full Text] [Related]
2. ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups.
Quinn DI; Ng CF; Grande E; Kwon TG; Linke R; Lee JL; Rosbrook B; Thakur MN; Eto M; Gross-Goupil M
ESMO Open; 2021 Jun; 6(3):100105. PubMed ID: 33901868
[TBL] [Abstract][Full Text] [Related]
3. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
Chamie K; Donin NM; Klöpfer P; Bevan P; Fall B; Wilhelm O; Störkel S; Said J; Gambla M; Hawkins RE; Jankilevich G; Kapoor A; Kopyltsov E; Staehler M; Taari K; Wainstein AJA; Pantuck AJ; Belldegrun AS
JAMA Oncol; 2017 Jul; 3(7):913-920. PubMed ID: 27787547
[TBL] [Abstract][Full Text] [Related]
6. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
[TBL] [Abstract][Full Text] [Related]
7. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
Rini BI; Melichar B; Ueda T; Grünwald V; Fishman MN; Arranz JA; Bair AH; Pithavala YK; Andrews GI; Pavlov D; Kim S; Jonasch E
Lancet Oncol; 2013 Nov; 14(12):1233-42. PubMed ID: 24140184
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
Ravaud A; Motzer RJ; Pandha HS; George DJ; Pantuck AJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Martini JF; Ramaswamy K; Casey M; Staehler M; Patard JJ;
N Engl J Med; 2016 Dec; 375(23):2246-2254. PubMed ID: 27718781
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract][Full Text] [Related]
13. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
[TBL] [Abstract][Full Text] [Related]
14. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
Haas NB; Manola J; Dutcher JP; Flaherty KT; Uzzo RG; Atkins MB; DiPaola RS; Choueiri TK
JAMA Oncol; 2017 Sep; 3(9):1249-1252. PubMed ID: 28278333
[TBL] [Abstract][Full Text] [Related]
16. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
Negrier S; Rioux-Leclercq N; Ferlay C; Gross-Goupil M; Gravis G; Geoffrois L; Chevreau C; Boyle H; Rolland F; Blanc E; Ravaud A; Dermeche S; Flechon A; Albiges L; Pérol D; Escudier B;
Eur J Cancer; 2020 Apr; 129():107-116. PubMed ID: 32146304
[TBL] [Abstract][Full Text] [Related]
17. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Voss MH; Bhatt RS; Vogelzang NJ; Fishman M; Alter RS; Rini BI; Beck JT; Joshi M; Hauke R; Atkins MB; Burgess E; Logan TF; Shaffer D; Parikh R; Moazzam N; Zhang X; Glasser C; Sherman ML; Plimack ER
Cancer; 2019 Jul; 125(14):2400-2408. PubMed ID: 30951193
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.
Patel A; Ravaud A; Motzer RJ; Pantuck AJ; Staehler M; Escudier B; Martini JF; Lechuga M; Lin X; George DJ
Clin Cancer Res; 2020 Sep; 26(18):4863-4868. PubMed ID: 32546645
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
Eisen T; Frangou E; Oza B; Ritchie AWS; Smith B; Kaplan R; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Bex A; Joniau S; Hancock B; Hermann GG; Bellmunt J; Hodgkinson E; Stewart GD; Barber J; Brown J; McMenemin R; Nathan P; Pickering LM; Parmar MKB; Meade A
J Clin Oncol; 2020 Dec; 38(34):4064-4075. PubMed ID: 33052759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
